Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jun 05, 2026
TickeronGET DAILY SIGNALS
The Cooper Companies (COO) Posts Record Revenue and Tenth Straight EPS Beat in Q2 2026

The Cooper Companies (COO) Posts Record Revenue and Tenth Straight EPS Beat in Q2 2026

Key Takeaways

  • Second quarter 2026 revenue reached a record $1.082 billion, rising 8% year-over-year and 5% organically.
  • Non-GAAP diluted EPS of $1.21 exceeded consensus estimates of $1.10, marking the tenth consecutive quarter of outperformance.
  • CooperVision revenue grew 8% to $723.5 million; CooperSurgical revenue increased 8% to $358.0 million.
  • GAAP EPS of $(0.40) reflected a $271.6 million pre-tax litigation charge tied to a prior product recall.
  • Company raised fiscal 2026 revenue and non-GAAP EPS guidance ranges.
  • Free cash flow totaled $96.4 million for the quarter.

Putting the Earnings in Context

The Cooper Companies operates in the medical device sector through its CooperVision contact lens and CooperSurgical women's health businesses. Fiscal second quarter results provide investors with an early read on demand trends in vision correction and fertility solutions amid evolving healthcare spending and competitive dynamics. Strong organic growth and consistent earnings beats underscore operational execution following last year's reorganization, while the litigation resolution clears a notable overhang and supports focus on long-term growth initiatives.

Breaking Down the Reported Results

For the fiscal second quarter ended April 30, 2026, The Cooper Companies reported revenue of $1.082 billion, an 8% increase from the prior-year period and 5% organically. CooperVision contributed $723.5 million (up 8%), while CooperSurgical added $358.0 million (up 8%). Non-GAAP diluted earnings per share reached $1.21, up 26% year-over-year and ahead of analyst expectations. GAAP diluted EPS was $(0.40) after a $271.6 million litigation charge related to a December 2023 voluntary recall of embryo culture media. Gross margin held steady at 68% on both GAAP and non-GAAP bases. The company updated fiscal 2026 guidance to revenue of $4.285–$4.321 billion and non-GAAP diluted EPS of $4.58–$4.66. I also checked this using Tickeron’s AI Screener to see how COO compares to others in the industry.

Market Reaction and Investor Sentiment

Shares of The Cooper Companies traded higher following the June 4 release, reflecting investor focus on the revenue record and non-GAAP earnings beat despite the one-time GAAP charge. Analysts highlighted the tenth straight quarter of outperformance and raised guidance as positive signals. Sentiment remains constructive on the company’s ability to deliver consistent growth while resolving legacy issues.

Forward Outlook and Key Factors to Monitor

With updated fiscal 2026 guidance in place, investors will watch for sustained organic revenue momentum in both CooperVision and CooperSurgical segments. Key areas include new product adoption in toric and multifocal lenses, demand trends in fertility solutions, and the impact of tariffs or currency fluctuations on margins.

Operational discipline remains a focus, with benefits expected from prior reorganization efforts. Free cash flow generation will be monitored closely as the company targets cumulative free cash flow exceeding $2.2 billion over fiscal years 2026–2028.

Broader industry dynamics such as healthcare utilization rates and competitive pricing in contact lenses could influence results. Upcoming quarterly updates will provide further visibility into guidance achievement and any strategic developments.

Using AI Tools for Deeper Analysis

One thing that stands out when reviewing results like these is how helpful AI-driven tools can be for putting numbers in perspective. I recently turned to Tickeron’s AI Screener to filter peers in the medical device space based on similar growth profiles and technical patterns. It allowed me to quickly scan thousands of stocks using customizable criteria such as fundamentals, volatility, and performance metrics, helping identify comparable trade ideas more efficiently than manual methods. From what I see, this kind of screening supports a more disciplined approach to monitoring names like COO alongside the broader sector. AI Screener

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: COO

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


COO sees MACD Histogram just turned negative

COO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 26 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for COO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 17 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COO as a result. In 55 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

COO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for COO crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

COO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 117 of 222 cases where COO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 53%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.424) is normal, around the industry mean (4.964). P/E Ratio (21.283) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.532) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (2.526) is also within normal values, averaging (56.876).

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. COO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
6101 Bollinger Canyon Road
Phone
+1 925 460-3600
Employees
15000
Web
https://www.coopercos.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.